Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure
The Beta-blocker Evaluation of Survival Trial (BEST)
Paul A. Grayburn, MD*,*,
Christopher P. Appleton, MD ,
Anthony N. DeMaria, MD ,
Barry Greenberg, MD ,
Brian Lowes, MD ,
Jae Oh, MD||,
Jonathan F. Plehn, MD¶,
Peter Rahko, MD#,
Martin St. John Sutton, MD**,
Eric J. Eichhorn, MD* the BEST Trial Echocardiographic Substudy Investigators
* Echocardiographic Core Laboratory, Baylor University Medical Center, Dallas, Texas
Mayo Clinic Scottsdale, Scottsdale, Arizona
University of California, San Diego, San Diego, California
University of Colorado, Denver, Colorado
|| Mayo Clinic Rochester, Rochester, Minnesota
¶ National Heart, Lung, and Blood Institute, Washington, DC
# University of Wisconsin, Madison, Wisconsin
** University of Pennsylvania, Philadelphia, Pennsylvania

View larger version (12K):
[in a new window]
|
Figure 1 Kaplan-Meier plot showing time to death by left ventricular (LV) end-diastolic volume index. Patients are stratified according to LV end-diastolic volume index 120 ml/m2 versus >120 ml/m2. E = events.
|
|
|